B-ALL. Credit: Reth Universitaet Freiburg
B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease. Their studies could change the way we think about clinical therapies for treating these tumour diseases. The scientists have published their research in the journal Nature.
B cells are white blood cells that produce antibodies against antigens, namely substances which the immune system recognises as foreign. Normal B cell development and maturation is regulated by a balance between kinase and phosphatase enzymes. These enzymes phosphorylate or de-phosphorylate the signalling subunits of the B cell antigen receptors (BCR). This means that the kinases add phosphate groups to the BCR, while the phosphatases remove them. Only if it has been phosphorylated by kinases is a BCR completely active and signals to the B cell that there is a foreign substance. This means that the kinases and phosphatases affect the receptor's capacity to send signals.
In B-ALL tumour cells, certain kinase enzymes, such as the Abelson tyrosine kinase (ABL), are altered and act as oncogenes, spurring the growth of tumours independently of the BCR. The B cells then continue to divide although they do not function. That is why this disease is treated with agents that inhibit the ABL kinase. However, resistant ABL mutants still often develop and the tumour continues to grow.
The American and German team investigated how BCR signalling in tumour cells is regulated. They discovered that the signalling subunits of the BCR in B-ALL tumour cells are hardly phosphorylated and that there is a higher number of inhibiting receptors on the cell's surface. Because these receptors bind phosphatases, they prevent the BCR from becoming active. When the researchers shut off the inhibiting receptors or the associated phosphatases, the B-ALL tumour cells died instantly. The researchers were also able to demonstrate in an animal experiment how a phosphatase inhibitor prevented tumours from spreading. By inhibiting the phosphatases, they essentially freed the BCR signalling pathways that the ABL kinase had been supressing. Because a B cell that has a disproportionate amount of active BCR receptors no longer has a balance of kinases and phosphatases, this form of therapy thus leads to cell death, or what is known as apoptosis.
Future ALL treatments could aim at inhibiting the phosphatases instead of the ABL kinases and thereby strengthen BCR signals. Reth said, "In the last few years, we have investigated at BIOSS the significance of the balance between kinases and phosphatases for the normal development of B lymph nodes. Now we've discovered that this also plays a role in the development and treatment of B cell tumours."
Reth is the scientific director of the cluster of excellence BIOSS Centre for Biological Signalling Studies. He is also a professor at the Institute of Biology III at the University of Freiburg and head of a research group at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg. Jumaa is now a professor at the Institute of Immunobiology at the University of Ulm and was a member of the BIOSS Centre for Biological Signalling Studies.
Explore further: Nanoscale ruler reveals organization of the cell membrane
More information: "Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia." Nature. DOI: 10.1038/nature14231
Medical Xpress on facebook
Related Stories
Could sticky cells cause drug resistance in chronic blood cancer?
(Medical Xpress)—Chronic myeloid leukaemia (CML) is associated with a specific genetic mutation that results from DNA on different chromosomes breaking off and swapping places. This disrupts genes at the ...
Targeting leukemia cell's gene 'addiction' presents new strategy for treatment
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveal ...
Nanoscale ruler reveals organization of the cell membrane
After a ten-year effort, Prof. Dr. Michael Reth from the Institute of Biology III of the University of Freiburg and the Max Planck Institute of Immunobiology and Epigenetics has developed a method to investigate ...
Anchoring ABL for a better fate
Chronic Myelogenous Leukemia (CML) is a cancer of the white blood cells that is most commonly found in adults and in the elderly. Its incidence has been estimated to be 1 to 2 in 100,000 people. CML was the first cancer to ...
Jak of all trades? Not of leukaemia therapy
About one in five or six cases of adult leukaemia in Western populations relates to so-called chronic myeloid leukaemia, or CML. Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition ...
Recommended for you
Angelina Jolie has ovaries removed over cancer fears
Hollywood megastar Angelina Jolie announced Tuesday that she has had her ovaries and fallopian tubes removed over fears of a hereditary form of cancer, following her double mastectomy two years ago.
Study indicates results of many breast biopsies may be in error
Women who have breast biopsies to diagnose cancer might want to think twice about the results of the procedures, according to a new study led by University of Washington researchers.
Mastectomies on the rise in Venezuela amid economic crisis
Oncologist Gabriel Romero performs hundreds of life-saving surgeries a year, but he no longer takes pleasure in his work.
Cancer patients want more information about medical imaging risk
A substantial gap exists between patient expectations and current practices for providing information about medical imaging tests that use radiation, according to a new study published online in the journal Radiology. Resear ...
New insights into survival outcomes of Asian Americans diagnosed with cancer
Numerous studies have documented racial differences in deaths from cancer among non-Hispanic whites and African Americans, but little has been known about survival outcomes for Asian Americans who have been ...
Metabolic compensation underlies drug resistance in glioblastoma
Gliobststoma (GBM) is a highly aggressive brain tumor that is resistant to many conventional cancer therapies. The kinase mTOR induces pathways that are aberrantly activated in GBM. However, mTOR inhibitors have not shown ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here to reset your password.
Sign in to get notified via email when new comments are made.
B-ALL. Credit: Reth Universitaet Freiburg
B cell acute lymphoblastic leukaemia, or B-ALL, is the most common tumour disease in children and also occurs in adults. It develops when signalling pathways in immature B cells, or pre-B cells, are dysregulated. Prof. Dr. Markus Müschen from the University of California in San Francisco, USA, and his team worked together with the BIOSS researchers Prof. Dr. Hassan Jumaa and Prof. Dr. Michael Reth to find a new approach for treating the B-ALL tumour disease. Their studies could change the way we think about clinical therapies for treating these tumour diseases. The scientists have published their research in the journal Nature.
B cells are white blood cells that produce antibodies against antigens, namely substances which the immune system recognises as foreign. Normal B cell development and maturation is regulated by a balance between kinase and phosphatase enzymes. These enzymes phosphorylate or de-phosphorylate the signalling subunits of the B cell antigen receptors (BCR). This means that the kinases add phosphate groups to the BCR, while the phosphatases remove them. Only if it has been phosphorylated by kinases is a BCR completely active and signals to the B cell that there is a foreign substance. This means that the kinases and phosphatases affect the receptor's capacity to send signals.
In B-ALL tumour cells, certain kinase enzymes, such as the Abelson tyrosine kinase (ABL), are altered and act as oncogenes, spurring the growth of tumours independently of the BCR. The B cells then continue to divide although they do not function. That is why this disease is treated with agents that inhibit the ABL kinase. However, resistant ABL mutants still often develop and the tumour continues to grow.
The American and German team investigated how BCR signalling in tumour cells is regulated. They discovered that the signalling subunits of the BCR in B-ALL tumour cells are hardly phosphorylated and that there is a higher number of inhibiting receptors on the cell's surface. Because these receptors bind phosphatases, they prevent the BCR from becoming active. When the researchers shut off the inhibiting receptors or the associated phosphatases, the B-ALL tumour cells died instantly. The researchers were also able to demonstrate in an animal experiment how a phosphatase inhibitor prevented tumours from spreading. By inhibiting the phosphatases, they essentially freed the BCR signalling pathways that the ABL kinase had been supressing. Because a B cell that has a disproportionate amount of active BCR receptors no longer has a balance of kinases and phosphatases, this form of therapy thus leads to cell death, or what is known as apoptosis.
Future ALL treatments could aim at inhibiting the phosphatases instead of the ABL kinases and thereby strengthen BCR signals. Reth said, "In the last few years, we have investigated at BIOSS the significance of the balance between kinases and phosphatases for the normal development of B lymph nodes. Now we've discovered that this also plays a role in the development and treatment of B cell tumours."
Reth is the scientific director of the cluster of excellence BIOSS Centre for Biological Signalling Studies. He is also a professor at the Institute of Biology III at the University of Freiburg and head of a research group at the Max Planck Institute of Immunobiology and Epigenetics in Freiburg. Jumaa is now a professor at the Institute of Immunobiology at the University of Ulm and was a member of the BIOSS Centre for Biological Signalling Studies.
Explore further: Nanoscale ruler reveals organization of the cell membrane
More information: "Signaling thresholds and negative B cell selection in acute lymphoblastic leukemia." Nature. DOI: 10.1038/nature14231
Medical Xpress on facebook
Related Stories
Could sticky cells cause drug resistance in chronic blood cancer?
(Medical Xpress)—Chronic myeloid leukaemia (CML) is associated with a specific genetic mutation that results from DNA on different chromosomes breaking off and swapping places. This disrupts genes at the ...
Targeting leukemia cell's gene 'addiction' presents new strategy for treatment
An international team of scientists studying acute forms of Leukaemia have identified a new drug target to inhibit the genes which are vital for the growth of diseased cells. The research, reported in EMBO Molecular Medicine, reveal ...
Nanoscale ruler reveals organization of the cell membrane
After a ten-year effort, Prof. Dr. Michael Reth from the Institute of Biology III of the University of Freiburg and the Max Planck Institute of Immunobiology and Epigenetics has developed a method to investigate ...
Anchoring ABL for a better fate
Chronic Myelogenous Leukemia (CML) is a cancer of the white blood cells that is most commonly found in adults and in the elderly. Its incidence has been estimated to be 1 to 2 in 100,000 people. CML was the first cancer to ...
Jak of all trades? Not of leukaemia therapy
About one in five or six cases of adult leukaemia in Western populations relates to so-called chronic myeloid leukaemia, or CML. Treatment of CML usually relies on inhibitors of the abnormal protein that causes the condition ...
Recommended for you
Angelina Jolie has ovaries removed over cancer fears
Hollywood megastar Angelina Jolie announced Tuesday that she has had her ovaries and fallopian tubes removed over fears of a hereditary form of cancer, following her double mastectomy two years ago.
Study indicates results of many breast biopsies may be in error
Women who have breast biopsies to diagnose cancer might want to think twice about the results of the procedures, according to a new study led by University of Washington researchers.
Mastectomies on the rise in Venezuela amid economic crisis
Oncologist Gabriel Romero performs hundreds of life-saving surgeries a year, but he no longer takes pleasure in his work.
Cancer patients want more information about medical imaging risk
A substantial gap exists between patient expectations and current practices for providing information about medical imaging tests that use radiation, according to a new study published online in the journal Radiology. Resear ...
New insights into survival outcomes of Asian Americans diagnosed with cancer
Numerous studies have documented racial differences in deaths from cancer among non-Hispanic whites and African Americans, but little has been known about survival outcomes for Asian Americans who have been ...
Metabolic compensation underlies drug resistance in glioblastoma
Gliobststoma (GBM) is a highly aggressive brain tumor that is resistant to many conventional cancer therapies. The kinase mTOR induces pathways that are aberrantly activated in GBM. However, mTOR inhibitors have not shown ...
User comments
Please sign in to add a comment. Registration is free, and takes less than a minute. Read more
Click here
to reset your password.
Sign in to get notified via email when new comments are made.
0 comments:
Post a Comment